| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2141.2003.04549.X |
| P698 | PubMed publication ID | 12956767 |
| P50 | author | Francisco España | Q56494030 |
| P2093 | author name string | Amparo Estellés | |
| Cristina Falcó | |||
| Justo Aznar | |||
| Esther Zorio | |||
| Luis Almenar | |||
| Ana Osa | |||
| Remedios Castelló | |||
| P2860 | cites work | TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex | Q28281969 |
| Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. | Q30757818 | ||
| Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. | Q31060214 | ||
| An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model | Q33902731 | ||
| Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor | Q34059019 | ||
| Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway | Q34104461 | ||
| Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients | Q42166279 | ||
| High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. | Q50755801 | ||
| Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. | Q50911423 | ||
| Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms | Q57611895 | ||
| Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISA's | Q69356466 | ||
| Assay of protein C in human plasma: comparison of amidolytic, coagulation, and immunochemical assays | Q69707359 | ||
| Inducible carboxypeptidase activity. A role in clot lysis in vivo | Q71102936 | ||
| Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study | Q72235431 | ||
| Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled | Q73662221 | ||
| Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe | Q74079222 | ||
| Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors | Q74290905 | ||
| A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels | Q74534641 | ||
| A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor | Q77387629 | ||
| Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infarction | Q77709657 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 958-965 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system | |
| P478 | volume | 122 |
| Q84784471 | +1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss |
| Q33631692 | Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population |
| Q79366427 | Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis |
| Q40048594 | Dose-Response Relationship Between Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) and Stroke: A Chinese Case-Control Study |
| Q84274982 | Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation |
| Q37207774 | Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men |
| Q33731941 | Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis |
| Q79799911 | The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis |
| Q33902971 | The fibrinogen γA/γ' isoform does not promote acute arterial thrombosis in mice |
| Q54092679 | Thrombin-Activatable Fibrinolysis Inhibitor Polymorphisms and Cerebral Venous Thrombosis in Mexican Mestizo Patients. |
| Q36546041 | Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease |
Search more.